Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors - Wikidata - awgldk - TriplyDB

Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors

Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors

http://www.wikidata.org/entity/Q28749672

about

sameAs

Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors.Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer's disease Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells CSAP localizes to polyglutamylated microtubules and promotes proper cilia function and zebrafish development Switching cell fate: the remarkable rise of induced pluripotent stem cells and lineage reprogramming technologies Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins Modeling Alzheimer's Disease with Induced Pluripotent Stem Cells: Current Challenges and Future Concerns A Compendium of Preparation and Application of Stem Cells in Parkinson's Disease: Current Status and Future Prospects Human induced pluripotent stem cells for monogenic disease modelling and therapy hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine Generation of diverse neural cell types through direct conversion The Application of Human iPSCs in Neurological Diseases: From Bench to Bedside The Progress of Induced Pluripotent Stem Cells as Models of Parkinson's Disease A Dishful of a Troubled Mind: Induced Pluripotent Stem Cells in Psychiatric Research Induced Pluripotency and Gene Editing in Disease Modelling: Perspectives and Challenges An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs Cell replacement therapy for central nervous system diseases Cell Therapy for Parkinson's Disease: New Hope from Reprogramming Technologies Using iPS Cells toward the Understanding of Parkinson's Disease Advancements in stem cells treatment of skeletal muscle wasting Induced pluripotent stem cell technology and direct conversion: new possibilities to study and treat Parkinson's disease Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs)Parkinson's disease: gene therapies Patient-specific induced pluripotent stem cells in neurological disease modeling: the importance of nonhuman primate models Pluripotent stem cells in research and treatment of hemoglobinopathies Using stem cells and iPS cells to discover new treatments for Parkinson's disease Progress toward establishing embryonic stem or induced pluripotent stem cell-based clinical translation A poor imitation of a natural process: a call to reconsider the iPSC engineering technique Non-viral methods for generating integration-free, induced pluripotent stem cells Current concept in neural regeneration research: NSCs isolation, characterization and transplantation in various neurodegenerative diseases and stroke: A review iPSCs and small molecules: a reciprocal effort towards better approaches for drug discovery Longitudinal measures of proteostasis in live neurons: features that determine fate in models of neurodegenerative disease Induced pluripotent stem cells as a disease modeling and drug screening platform Primary skin fibroblasts as a model of Parkinson's disease Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions

P2860

Q54903613-AB352B0F-D7C9-4048-9D4C-0202A7F6F770 Q54903614-DFC7E93C-E3CB-4273-99B1-2510CD55DD4A Q54946787-8364146B-1DCF-457E-A037-E885582A48AC Q54946788-BDBF5829-B8FE-4020-9ECF-913E5E45D17D Q54946790-B4315DE7-B43D-4006-9B7F-142AC3B252E9 Q54946791-7048226D-E30D-4AFA-8EC1-07462B3E3154 Q54946792-94745F01-0FBC-4676-AEE2-9BD0A4F4C2A3 Q54946793-DAAC8A06-7934-431B-9ED7-79343E84DA1F Q54946794-BA241AFA-D545-4BC8-8333-D8EAF6B68977 Q54946795-CF047087-8D80-4825-B68E-AE8417294AFD Q54946796-4E7599BF-7BD9-4C63-A27C-58E6F47ED8A0 Q54946797-B7A87D1D-659B-4BB7-A62D-095275EE4D55 Q54946799-151EEEE7-5F74-4958-932F-61AA2F0056E3 Q54946800-0B60C7AD-00DA-48A4-9C83-27752A282384 Q54946801-EA727E46-E5CA-4787-BB59-0E53B2DFA5FE Q54946802-AEBFB723-BC44-4D58-8B5D-2382D129916B Q54946803-26B8B7E9-9943-48BC-83DC-30C35CCB01EC Q54946804-FB38663C-F683-48DA-A47D-4EB64570CB75 Q54946805-BD994989-B283-4CB5-96EA-7A5B08FA2945 Q54946810-47D160ED-DAFD-4C8F-B4FE-C4E309C22F36 Q54946811-AA1743C7-3A72-4C9A-A1AF-B2942BE499E8 Q54946812-3C786412-A58E-4DFC-87D8-A42EE393D488 Q54946813-F3E0385E-BCF7-457A-A466-D2FD445B7100 Q54946814-0C1B334A-C438-41B0-9868-C1207A7F1818 Q54946815-712CEB75-E9C5-4A27-975B-FB8A7DB537A5 Q54946816-9A03A890-42BF-443C-8AED-C3CA111B362A Q54946817-36DD0769-FB25-4B07-AF53-5D0662D61892 Q54946818-1AA0F6E9-714C-4955-993D-8E8600994CDC Q54946819-EEC75083-B823-4205-AC1C-3E309FD1205B Q54946821-C59B9782-B1F9-4005-83A9-B910BA6A5E34 Q54946822-4A9DDB33-ACFB-4FF1-B1C6-301C9A63BA54 Q54946823-EEAD87F4-4CD2-4CC8-ADAB-DA6918089EE4 Q54946824-2CBDC018-E992-4196-8F3B-B07E7F1F8A79 Q54946826-8A85E0C8-DDCB-4570-9365-091D298F128D Q54946827-986396E4-F0D0-485D-AFF8-ABC9BB80548A Q54946829-F4D8270F-673C-4113-B29E-34C699FD0C31 Q54946830-32A48428-6B76-45A3-AF05-BA1B9955532D Q54946831-DB86FC2C-BE86-40FB-8708-E86B31937721 Q54946832-607CA19B-7009-405D-9254-E512DCF623A4 Q54946833-7C0FB21A-330E-4208-91F7-B9F2528BAB6D

P1343

Q21284148-111AF9D2-D073-469B-AF1D-0A7DEA3ADBAF Q21562116-E216C81E-6E96-4558-B9C4-02D581BC7519 Q21999273-55A8EFC9-A0D9-4FF5-9A1B-356EC423C3CB Q24294466-316FF2CE-6310-440E-A3CE-EB2612A20E25 Q24300095-D723B41F-8494-4BF5-9981-8B11A6FBF26C Q24312744-F242EE97-D309-4C48-9E38-9F38AF738D9E Q24617141-E9A37A47-7F0C-4AE5-8AE5-98477447E888 Q24617599-931B0283-D424-4374-8DBC-BE619846C01E Q24620932-E0D92F24-AB2B-4ED6-989F-4462D6FE4CDB Q24632072-A2423A4A-D4AF-4025-B44B-F806FB309071 Q24653753-D0A353C7-6DCC-4F58-9BC9-7B95A87D3B4B Q26745513-39456B6E-69E5-42E4-969F-0314DA42D0E4 Q26746033-88598AB6-7C6C-4FC2-B117-B5E1631DDC70 Q26750393-537C6B13-CB7E-4F36-A2D5-B5815DDBE3E6 Q26751506-C0CCBCB7-F09B-40DF-88F4-506C10883D7B Q26765258-F9CAFC53-4252-4586-A011-9B8C65B4C370 Q26765876-3D6B969A-F455-4A7F-91F7-BDD8B8086606 Q26765894-DCE027AB-63C1-457D-AC1B-123E04FAABEC Q26770097-9EEF85E3-0A44-4EE0-B640-4E044DEF61E2 Q26775061-36B498CE-A13E-4688-875E-70D583A5A558 Q26775122-0CF7A060-D4E4-4E9E-A692-A08EAEE1EC37 Q26775791-8552B174-1264-435F-BB20-E39A39A7BC31 Q26776041-7415C8B3-1A8B-4F0B-AD15-73AEE451BE38 Q26799590-51A52599-A0D8-43DD-A68A-DBA65EA593C8 Q26822437-61B4F278-85F5-4B19-AFFE-13D0F1619CA7 Q26823333-EE394BF9-3512-44B0-8AC9-7E50F2F01F99 Q26823798-B95293A7-5D66-4ECB-A5E0-4DB664750B8A Q26824184-3D4CFE01-A5A3-4324-B40B-61F04863C984 Q26825524-D5B80EA9-2E94-411B-95A8-43D94B2FAFE5 Q26825713-348B8065-757E-4A20-9423-2DD09469D517 Q26825867-8AADEEC2-D1D1-4AAF-8B36-034FEEBEBC38 Q26827349-11463F1A-2BF7-4149-AB32-65000FAEBCB0 Q26851933-7DA5DD55-6E19-4B8C-AFF3-DC67738E019B Q26861483-C980DB2E-6142-400A-82C1-44FEBCFFBCFA Q26861926-EB1B8EB9-40DC-4607-918F-228B3F7811BC Q26865055-CF72F7C1-CCEC-4D30-A0B1-617F81482AEB Q26865220-B510DDBF-C2C8-4259-8788-1DA1F06F7C89 Q26865689-6698CD40-5900-469F-AA04-C4D7A73230A5 Q26999310-E1705627-4862-49B0-9111-62431A9DD690 Q27001159-A032CABE-4EA1-4F06-9632-76A15B15BC1D

P2860

Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors

http://www.wikidata.org/entity/Q28749672

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Parkinson's disease patient-de ...... of viral reprogramming factors

@ast

Parkinson's disease patient-de ...... of viral reprogramming factors

@en

Parkinson's disease patient-de ...... of viral reprogramming factors

@nl

type

label

Parkinson's disease patient-de ...... of viral reprogramming factors

@ast

Parkinson's disease patient-de ...... of viral reprogramming factors

@en

Parkinson's disease patient-de ...... of viral reprogramming factors

@nl

prefLabel

Parkinson's disease patient-de ...... of viral reprogramming factors

@ast

Parkinson's disease patient-de ...... of viral reprogramming factors

@en

Parkinson's disease patient-de ...... of viral reprogramming factors

@nl

P1433

Q28749672-74D68A63-9BB6-4460-810A-91B7240FD780

P1476

Q28749672-81A6CFF9-0CE0-4539-85F9-67C345D0792E

P2093

Q28749672-52747210-EC38-40E7-B026-C59B57C0B1B4

Q28749672-53D6F493-FCEA-4212-8AB0-AA2B3265E993

Q28749672-5D3A1966-1144-4E8A-8DF9-46945BFFB9F2

Q28749672-64801902-16D2-4899-A4B8-89D08CDD6857

Q28749672-8B8B7286-D63A-42A1-A94A-2D94D915ABD0

Q28749672-96955811-E79C-4821-B51E-F025F98BC2C5

Q28749672-AAE2A191-18F3-44F9-BB97-0EB907CF11DE

Q28749672-BD73C247-8B90-4236-9304-51B6C4BD2E9D

P2860

Q28749672-091D535F-DFB5-424E-960D-17CAADF35BCB

Q28749672-158C65CA-CE30-496A-8FA2-5935DEC20631

Q28749672-1A9BAC9A-A3AD-41EF-BAB7-7C2676D8AE1B

Q28749672-21DE150A-5562-4F70-98D6-AA1E6FD3FAFF

Q28749672-246AF9CF-833F-4037-9CA2-B99374B5F56D

Q28749672-29136972-7DF5-4433-A94B-18D4E526D26E

Q28749672-2BF79C06-600F-4C8B-89B6-57D9A0DF136A

Q28749672-3DAE8A99-1B89-4177-A310-EFF6A84B4B11

Q28749672-404F84E9-FA07-418F-94DE-5CD47B3C96DF

Q28749672-4281D8AD-1C26-495E-9F28-4DDC6CE775F6

P304

Q28749672-3D271BFC-6828-4383-9A85-3DBB79B48949

P31

Q28749672-2A01B6C9-0081-47E0-8817-2D4223581439

P3181

Q28749672-20F239E0-2387-414A-B532-246E7E309A26

P356

Q28749672-18A66498-5D94-4B2C-9AA4-B961BF2EE41F

P407

Q28749672-14FE52A4-E6D6-44D2-909F-D5F4B2D3675A

P433

Q28749672-B76F9749-26F6-418C-9B01-FF6FC60F6E9E

P4510

Q28749672-055B9725-C26A-4B73-9A79-D6E5D031441E

Q28749672-19B8250B-541E-4A7E-A13A-D48338EB34F4

Q28749672-1B5CA595-6634-427B-B61F-A54FA95EDA0E

Q28749672-1DC7E820-74B0-4BF2-978A-EA2F7CB4DA81

Q28749672-23E8B497-0880-4B0D-AB50-FE16A1C45210

Q28749672-286FF2D8-30B8-428F-86CC-506F747CBBB0

Q28749672-298FF7F6-EFC9-4173-8D39-EA66366EEE25

Q28749672-2BA6ED19-783B-4A45-A5AB-088239686B07

Q28749672-430A0C58-C734-4601-A6CD-9706053FD764

Q28749672-4E332447-FE09-4F43-9A6C-1259D0B21151

P478

Q28749672-ACC54003-B86B-44F1-871C-13F6273B422B

P50

Q28749672-2254C675-62C1-4726-B7B4-2D6E9CA13B05

Q28749672-AA3F1BFE-BB68-43BC-9063-A527766709BA

Q28749672-C362D4D0-856A-4883-BB2E-BEFA158AD76D

Q28749672-F896A5B7-FE59-4237-BAD5-7F99A36C9A00

P577

Q28749672-CDD2F520-376C-4329-8F8E-F3E258BE617C

P5875

Q28749672-773DD110-A5D7-4192-987B-BE63D0C78C69

P698

Q28749672-B901BA63-39BF-4671-A6E3-CA77B14660B6

P921

Q28749672-3131430F-0C95-48EF-B605-0477463C9C80

Q28749672-DC22981D-7723-41A4-AAC3-26C5758E560A

Q28749672-EF669822-04CC-4175-BC96-18131D423A3E

P932

Q28749672-16FB9741-202F-4055-965A-31763CD9C204

P3181

P356

J.CELL.2009.02.013

P1433

P1476

Parkinson's disease patient-de ...... of viral reprogramming factors

@en

P2093

Alexandra Blak

http://www.w3.org/2001/XMLSchema#string

Caroline Beard

http://www.w3.org/2001/XMLSchema#string

Elizabeth G Cook

http://www.w3.org/2001/XMLSchema#string

Frank Soldner

http://www.w3.org/2001/XMLSchema#string

Gunnar Hargus

http://www.w3.org/2001/XMLSchema#string

Maisam Mitalipova

http://www.w3.org/2001/XMLSchema#string

Ole Isacson

http://www.w3.org/2001/XMLSchema#string

Qing Gao

http://www.w3.org/2001/XMLSchema#string

P2860

Disease-specific induced pluripotent stem cells

Induced pluripotent stem cell lines derived from human somatic cells

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

Induction of pluripotent stem cells from adult human fibroblasts by defined factors

Generation of germline-competent induced pluripotent stem cells

Reprogramming of human somatic cells to pluripotency with defined factors

In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state

Induced pluripotent stem cells from a spinal muscular atrophy patient

Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes

Generation of mouse induced pluripotent stem cells without viral vectors

P304

964-77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1179593

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CELL.2009.02.013

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P4510

PDB1lox-17GFP-29

PDB1lox-17GFP-55

PDB1lox-17Puro-10

PDB1lox-17Puro-12

PDB1lox-17Puro-31

PDB1lox-17Puro-33

P478

136

http://www.w3.org/2001/XMLSchema#string

P50

Dirk Hockemeyer

Rudolf Jaenisch

P577

2009-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24184915

http://www.w3.org/2001/XMLSchema#string

P698

19269371

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

2787236

http://www.w3.org/2001/XMLSchema#string